Fig. 6.

Use of the BRCAness signature to predict for targeted therapies reveals that the survivin inhibitor YM-155 specifically targets BRCA-like cells. a Volcano plot of compounds predicted to target BRCA-like cells based on the BRCAness signature score. b Viability curves following 72 h of treatment with identified BRCAness-targeting molecules for BRCA1 mutant COV362, BRCA-like A2780, and non-BRCA-like ES2 and OVCAR8. c Viability curves following 72 h of treatment with drugs that BRCA-like cells are predicted to be resistant to